Atriva: Targeting Patients, Not Virus, Is The Way Forward In Flu
Executive Summary
Emerging Company Profile: Four-year-old Atriva Therapeutics GmbH is developing a drug to prevent the proliferation of flu virus by transiently inhibiting one of the patient’s own cellular processes, a host-mediated novel mechanism of action that could be effective against a range of respiratory virus infections.
You may also be interested in...
Keeping Track: US FDA Clears Novel Flu Treatment Xofluza, Boosts Trintellix Label With Sexual Dysfunction Data
The latest drug development news and highlights from our FDA Performance Tracker.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.